Recursion Pharmaceuticals, Inc.

RXRX

$3.44

+1.78%

2026-09-03 16:00:00 EDT+$0.06

Healthcare

Biotechnology

NASDAQ

Active Trading

Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery ...

Insider Transactions of RXRX

Acquisitions (A)

Since Jun 17, 2026

Disposals (D)

Since Jun 17, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Sep 1, 2026	Borgeson Blake	director	Class A Common Stock	D	30,000	$3.34
Aug 17, 2026	Khan Najat	director, officer: CEO and President	Class A Common Stock	D	80,498	$3.16
Aug 17, 2026	Hallett David	officer: Chief Scientific Officer	Class A Common Stock	D	26,657	$3.16
Aug 17, 2026	Taylor Ben R	officer: Chief Financial Officer	Class A Common Stock	D	25,018	$3.16
Aug 4, 2026	Borgeson Blake	director	Class A Common Stock	D	30,000	$3.25

Insider Trading Snapshot

Acquisitions (A)

Disposals (D)

Total Shares Bought

97,280

Total Shares Sold

236,136

Monthly Insider Activity

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Transactions by Title - Shares

X-axis: shares, sorted by total shares desc

Transactions by Title - Counts

X-axis: counts, sorted by A+D counts desc

Key People: Buy/Sell Activity and Price

Khan Najat

director, officer: CEO and President • 1 txns

Borgeson Blake

director • 4 txns

Hallett David

officer: Chief Scientific Officer • 1 txns

Taylor Ben R

officer: Chief Financial Officer • 1 txns

Transactions Table

Date	Executive	Title	Security	Side	Shares	Price	Value
Sep 1, 2026	Borgeson Blake	director	Class A Common Stock	D	30,000	$3.34	$100,200.00
Aug 17, 2026	Khan Najat	director, officer: CEO and President	Class A Common Stock	D	80,498	$3.16	$254,373.68
Aug 17, 2026	Hallett David	officer: Chief Scientific Officer	Class A Common Stock	D	26,657	$3.16	$84,236.12
Aug 17, 2026	Taylor Ben R	officer: Chief Financial Officer	Class A Common Stock	D	25,018	$3.16	$79,056.88
Aug 4, 2026	Borgeson Blake	director	Class A Common Stock	D	30,000	$3.25	$97,500.00
Jul 7, 2026	Borgeson Blake	director	Class A Common Stock	D	40,000	$3.96	$158,500.00
Jul 1, 2026	Dar Zavain	director	Class A Common Stock	A	5,109	—	—
Jul 1, 2026	Li Dean Y	director	Class A Common Stock	A	3,747	—	—
Jun 18, 2026	Bumpus Namandje	director	Class A Common Stock	D	3,963	$3.18	$12,602.34
Jun 17, 2026	Borgeson Blake	director	Class A Common Stock	A	88,424	—	—

Supply Chain of RXRX

RELATIONS

Upstream

NVIDIA CorporationNASDAQ:NVDA Google Cloud (Alphabet Inc.)NASDAQ:GOOGL Molecular Devices (Danaher Corporation subsidiary)NYSE:DHR Beckman Coulter (Danaher Corporation subsidiary)NYSE:DHR Tempus AI, Inc.NASDAQ:TEMHelix (Helix OpCo LLC)Splunk (Cisco Systems, Inc.)NASDAQ:CSCO Thermo Fisher Scientific Inc.NYSE:TMO Taiwan Semiconductor Manufacturing Company (TSMC)NYSE:TSM

Downstream

Roche Holding AG / GenentechSIX:ROGSanofi S.A.NASDAQ:SNYBayer AGXTRA:BAYNMerck KGaAXTRA:MRK

Proxies

Schrödinger, Inc.NASDAQ:SDGR Relay Therapeutics, Inc.NASDAQ:RLAYExscientia plc (former)UnconfirmedAbCellera Biologics, Inc.NASDAQ:ABCL

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer